New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareKisspeptin-10 vs Dermorphin

Kisspeptin-10 vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10
Recovery & Repair
Dermorphin
Summary
Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
SubQ, IV
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
50–500 mcg
Not established for human use; research doses vary widely
Frequency
Once daily to every other day
Not established
Key Benefits
  • Potently stimulates LH and testosterone
  • Enhances sexual arousal and libido
  • Activates HPG axis — upstream of GnRH
  • May improve fertility in hypogonadotropic hypogonadism
  • Increases brain activation in sexual attraction circuits
  • May restore LH pulsatility in suppressed HPG axis
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Injection site reactions
  • Temporary nausea
  • Flushing
  • Elevated LH/testosterone (intended effect)
  • +1 more
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With